Journal
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
Volume 89, Issue 12, Pages 6130-6138Publisher
ENDOCRINE SOC
DOI: 10.1210/jc.2004-0909
Keywords
-
Categories
Funding
- NCI NIH HHS [CA90970, R01 CA090970, CA095681, R01 CA095681, CA109379, R01 CA109379] Funding Source: Medline
Ask authors/readers for more resources
Proline-, glutamic acid-, and leucine-rich protein-1) PELP1/MNAR [modulator of nongenomic activity of estrogen receptor (ER)], a novel coregulatory protein, modulates genomic as well as nongenomic activity of ERs. We characterized the expression and localization of PELP1 in both benign and cancerous endometrium. Our results suggest that PELP1 is expressed in all stages of endometrium; however, this protein exhibits distinct localization depending on the phase. PELP1 is expressed in both the stroma and epithelial cells. Using the Ishikawa endometrial cancer model cell line and ER subtype-specific ligands, we found that PELP1 functionally interacts with both ERalpha and ERbeta and enhances their transcriptional responses. However, in endometrial cancer cells, endogenous PELP1is also required for optimal ligand-mediated transcription and proliferation responses. PELP1 promoted a tamoxifen-mediated agonistic action in endometrial, but not in breast cancer cells. PELP1 expression and localization are widely deregulated in endometrial cancers. In addition, PELP1 and ERbeta were localized predominantly in the cytoplasm of high-grade endometrial tumors. Our results suggest that PELP1 plays an essential role in the proliferation of cancerous endometrial cells.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available